Literature DB >> 1928271

Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis.

H M Leibowitz1.   

Abstract

Two hundred eighty-eight cases of culture-proven bacterial conjunctivities were evaluated as part of two multicentered, randomized, prospective clinical studies comparing the antibacterial efficacy of topically administered ciprofloxacin 0.3% either with a placebo or with tobramycin 0.3%. In the first study, ciprofloxacin was significantly (P less than .001) more effective than the placebo. It eradicated or reduced the various bacterial pathogens in 93.6% of patients, compared to 59.5% for the placebo. In the second study, ciprofloxacin (94.5%) and tobramycin (91.9%) were equally effective. Topically applied ciprofloxacin eradicated or reduced all isolated bacterial species, attesting to its broad antibacterial spectrum and its potential usefulness in treating external ocular infections.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1928271

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  26 in total

Review 1.  Topical antibiotics for acute bacterial conjunctivitis: a systematic review.

Authors:  A Sheikh; B Hurwitz
Journal:  Br J Gen Pract       Date:  2001-06       Impact factor: 5.386

Review 2.  Eye disorders: bacterial conjunctivitis.

Authors:  C W Chung; E J Cohen
Journal:  West J Med       Date:  2000-09

3.  Shifting trends in in vitro antibiotic susceptibilities for common bacterial conjunctival isolates in the last decade at the New York Eye and Ear Infirmary.

Authors:  Adebukola Adebayo; Jignesh G Parikh; Steven A McCormick; Mahendra K Shah; Remedios S Huerto; Guopei Yu; Tatyana Milman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-06-08       Impact factor: 3.117

4.  Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children.

Authors:  Jesse DeLeon; Bruce E Silverstein; Catherine Allaire; Lynne S Gearinger; Kirk M Bateman; Timothy W Morris; Timothy L Comstock
Journal:  Clin Drug Investig       Date:  2012-05-01       Impact factor: 2.859

Review 5.  Bacterial conjunctivitis.

Authors:  John Epling
Journal:  BMJ Clin Evid       Date:  2012-02-20

6.  Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials.

Authors:  Timothy L Comstock; Michael R Paterno; Dale W Usner; Michael E Pichichero
Journal:  Paediatr Drugs       Date:  2010-04-01       Impact factor: 3.022

Review 7.  Treatment of ocular infections with topical antibacterials.

Authors:  J P Leeming
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

8.  3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children.

Authors:  Isabelle Cochereau; Amel Meddeb-Ouertani; Moncef Khairallah; Abdelouahed Amraoui; Khalid Zaghloul; Mihai Pop; Laurent Delval; Pascale Pouliquen; Radhika Tandon; Prashant Garg; Pablo Goldschmidt; Tristan Bourcier
Journal:  Br J Ophthalmol       Date:  2006-10-18       Impact factor: 4.638

9.  Acute infectious conjunctivitis in childhood.

Authors:  R Chawla; J D Kellner; W F Astle
Journal:  Paediatr Child Health       Date:  2001-07       Impact factor: 2.253

10.  Effectiveness, tolerability and safety of azithromycin 1% in DuraSite for acute bacterial conjunctivitis.

Authors:  Susannah McLean; Aziz Sheikh
Journal:  Patient Prefer Adherence       Date:  2010-05-13       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.